31 results about "Receptor targeting" patented technology

The invention belongs to the technical field of biomedical imaging, and particularly discloses an in-vivo imaging method of an SAPAP3 gene defect disease model, which is characterized in that an effective dose of an S1PR1 receptor targeted radioactive probe is injected into the body of the SAPAP3 gene defect disease model. According to the method, an S1PR1 receptor targeting radioactive probe is utilized, the technical bottleneck that in-vivo and dynamic observation of the S1PR1 receptor cannot be achieved through an existing in-vitro technology is solved, and an indispensable visual tool and a quantitative evaluation means are provided for studying the neurobiological mechanism of related mental diseases such as obsessive-compulsive disorder and accelerating research and development of related drugs.

The application discloses a PROTAC compound with RORgamma t receptor targeted degradation and purposes thereof, which is a compound with a structure shown in a general formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition thereof. e is a ligand capable of combining with an E3 ubiquitin ligase; the L is a linking group covalently combining at least one R e and at least one R W ; the R w is a target protein RORgamma t binding ligand; the application is based on the target point of RORgamma t and the PROTAC technology, and a series of RORgamma t-PROTACs are designed and synthesized for the first time. The mechanism is that the target protein ligand and the E3 ubiquitin ligase ligand are combined with POI and E3 ligase respectively, so as to form a ternary complex of "POI-PROTAC-E3 ligase". Then, the POI is marked with a ubiquitination label, and is degraded by a proteasome. The advantages of RORgamma t-PROTACs mainly include targeting of "undruggable proteins", small dosage, low toxicity, and difficulty in drug resistance. W -L-R e (I)

This invention relates to the field of biomedicine, and more particularly to a hair follicle-targeted delivery system and a hair growth and anti-hair loss cosmetic. The hair follicle-targeted delivery system comprises: a lipid nanoparticle core loaded with bioactive ingredients having hair growth and anti-hair loss effects; a hair follicle-targeting molecule capable of specifically recognizing and binding to receptors on the surface of hair follicle cells; and a targeting and anchoring conjugate consisting of a linker covalently linked to the hair follicle-targeting molecule and an anchoring lipid. The targeting and anchoring conjugate is embedded in the lipid bilayer of the lipid nanoparticle core via the anchoring lipid, thereby exposing the hair follicle-targeting molecule on the surface of the lipid nanoparticle core. This application, through its innovative targeting and anchoring conjugate structure, can significantly improve the targeting and enrichment efficiency of the hair growth and anti-hair loss active ingredients on hair follicle tissue, ensuring precise drug action on the lesion site, thereby significantly increasing the number of hair follicles in the alopecia areata modeling area.

The invention discloses a functionalized targeting fluorescent nanoprobe and application thereof in protein mutation analysis, and relates to the technical field of biology, the fluorescent nanoprobe comprises a targeting molecule-PEG hydrophilic bridging molecule and a matrix; the preparation method comprises the following steps: adding nano-seeds into fluorescent molecules to prepare fluorescent nano-particles, and stirring and mixing the fluorescent nano-particles with targeting molecules-PEG hydrophilic bridging molecules; the method is combined with deep learning to be applied to protein mutation analysis. The multifunctional integrated protein mutation receptor targeted fluorescent nanoprobe provided by the invention can accurately mark the position of a mutant protein at a single cell level, and can realize in-situ, real-time and dynamic living cell imaging of a tumor cell endogenous molecular mutant protein; and qualitative and quantitative analysis of tumor cell protein mutation can be realized through subcellular localization of the targeted fluorescent nanoprobe.

Provided are methods of treating myelodysplastic syndrome (MDS), oligoblastic acute myelogenous leukemia (O-AML), or chronic myelomonocytic leukemia (CMML) using 765IGF-MTX and other IGF-receptor-targeted agents, and formulations for delivering 765IGF-MTX and other IGF-receptor-targeted agents to patients. Also provided are pharmaceutical compositions for use in treating MDS, O-AML, and CMML.

Provided are a multifunctional genetically modified immune cell, and a preparation method and use therefor. The multifunctional gene modification vector carries an isolated nucleic acid. The isolated nucleic acid comprises: a first nucleic acid fragment, a second nucleic acid fragment and a third nucleic acid fragment. The first nucleic acid fragment, the second nucleic acid fragment and the third nucleic acid fragment are connected. The first nucleic acid fragment is used for encoding an antigen chimeric receptor targeting a NKp30 ligand. The second nucleic acid fragment is used for encoding a fusion protein, wherein the fusion protein comprises IL-15 and IL-15 Rα, and IL-15 is connected to IL-15 Rα. The third nucleic acid fragment is used for encoding a CXCR2 receptor. Therefore, the multifunctional genetically modified immune cell prepared by using the multifunctional gene modification vector can improve the specific killing ability, survival ability, proliferation ability and tumor infiltration ability of the immune cell, so that the clinical curative effect of the immune cell is further improved.

This application discloses a compound or a pharmaceutically acceptable salt thereof, said compound comprising a compound of formula (I) or a compound of formula (II). A radioactive element preparation comprising thereof and a radioactive element chelated therewith is also disclosed. Its use in the preparation of reagents targeting CXCR4, particularly CXCR4 tracers, more particularly in vivo CXCR4 tracers, or reagents that specifically bind to cells expressing CXCR4 is also disclosed. [Targeting Peptide-I]-Xaa1-X 1 (R 1 )L 1 -[Connector]-R x n1 (I), R x n1 -[Connector]-X 1 (R 1 )L 1 -Xaa1-[targeting peptide-II](II).

The present application relates to the technical fields of biological medicine and cellular immunotherapy, and particularly relates to a signal conversion receptor targeting IL-10, an engineered macrophage and application thereof. The signal conversion receptor is composed of an extracellular domain and a transmembrane domain and an intracellular domain derived from TLR9, and the extracellular domain sequentially comprises a signal peptide, a HA tag and a specific binding domain of an IL-10 receptor alpha subunit from N-terminal to C-terminal. The present application further prepares an engineered macrophage SR CAR-M capable of specifically recognizing IL-10 and converting it into a TLR9 activation signal, which can induce macrophages to polarize to M1 type and has excellent phagocytosis and killing capacity for bladder cancer, breast cancer, lung cancer and melanoma cells, and can be used for preparing related tumor treatment drugs, overcoming the common problems of existing cell therapy, such as easy exhaustion, difficult infiltration and easy inhibition in solid tumors, and having significant clinical transformation potential.

The invention provides a GSH (glutathione) reduction response type targeted nano-drug based on chondroitin sulfate as well as a preparation method and application of the GSH reduction response type targeted nano-drug. Chondroitin sulfate with CD44 receptor targeting ability and an anti-cancer drug camptothecin are covalently linked through a disulfide bond sensitive to GSH, and the constructed novel targeting nano-drug can accurately recognize human colorectal cancer tumor cells highly expressed by a CD44 receptor in a targeting manner. Meanwhile, the high-concentration glutathione at the tumor site can oxidize and reduce the disulfide bond to cause the fracture of AC-CPT NPs, so that the effective release of the camptothecin medicine at the tumor site is realized, and the anti-tumor effect is further enhanced. The reduction response type targeting nano-drug prepared by the invention solves the problems of poor targeting and biological solubility and limited treatment effect of the traditional anti-cancer drug camptothecin, and provides an innovative strategy for realizing accurate targeting and efficient treatment of cancers.

This invention discloses a folic acid receptor-targeting compound and its uses, belonging to the field of pharmaceutical technology. The folic acid receptor-targeting compound is a compound of formula (I), its stereoisomer, its crystalline hydrate, its deuterated derivative, its solvate, its prodrug, or a pharmaceutically acceptable salt thereof: [target]-(L x ) s -R x (I), where [target] is a folic acid receptor-binding ligand; R x The chelating group is Ch or the prosthetic group is PG; s is an integer from 1 to 10; L x It contains at least one L 3 and with AA, L 1 L 2 or L 3 Arbitrary combinations are possible. The folic acid receptor-targeting compounds of this invention have low KD values ​​and strong affinity between the ligands and receptors, and can be used as folic acid receptor-targeted radiotherapy agents for imaging, diagnosis, and treatment of folic acid receptor (FR)-expressing tumors or cells.

The invention belongs to the technical field of medicines, and discloses a paclitaxel and silver nanoparticle loaded lipidosome nano-targeting preparation as well as preparation and application of the paclitaxel and silver nanoparticle loaded lipidosome nano-targeting preparation. According to the invention, nano-particles coated with silver nano-particles are prepared by adopting a film dispersion method. The nano-drug provided by the invention is helpful for solving the problems of poor water solubility, low bioavailability, poor tumor targeting property, strong toxic and side effects and the like of an anti-cancer drug paclitaxel and low bacterial uptake efficiency of an antibacterial drug Ag Nps, and provides a hyaluronic acid coated CD44 receptor targeted paclitaxel and Ag Nps co-loaded liposome nano-targeting preparation, so that the anti-tumor effect is improved. The preparation process is simple, the cost is low, the stability is good, and the repeatability is high.

The invention discloses a cell membrane bionic magnetic nano-microsphere based on cannabinoid receptor CB2 receptor targeting, a preparation method of the cell membrane bionic magnetic nano-microsphere and application of the cell membrane bionic magnetic nano-microsphere to analgesic screening. The cell membrane bionic magnetic nano-microsphere takes a surface aldehyde group modified magnetic nano-microsphere as a core; a cell membrane of a high-expression cannabinoid receptor CB2 is wrapped on the surface of a magnetic bead by using a covalent bond binding method, a potential agonist is screened based on ligand-receptor affinity interaction, the active ligand of the cannabinoid receptor CB2 is efficiently captured by using a bionic magnetic nano material fishing technology, active components can be rapidly and sensitively screened out, and the application prospect is wide. The method is simple in operation, reduces analysis steps and time, improves analysis accuracy, remarkably improves separation efficiency and specificity of trace active components in a complex system by adopting collaborative innovation of a magnetic nano material and a biomimetic membrane technology, and has a great application prospect.

This invention discloses the application of GRP94 protein as a drug delivery target in the construction of drug carriers for Parkinson's disease. GRP94 is highly upregulated on the cell membranes of dopaminergic neurons in the substantia nigra of Parkinson's disease cells, while its expression is extremely low on the surface of normal brain cells. The invention also discloses the application of GRP94 as a target in a targeted delivery system for anti-Parkinson's disease drugs. By targeting GRP94, the delivered anti-Parkinson's drug can efficiently penetrate the blood-brain barrier to reach the brain parenchyma, avoiding normal brain cells and specifically targeting dopaminergic neurons in the substantia nigra of Parkinson's disease cells, thus achieving targeted drug delivery for Parkinson's disease. This invention applies GRP94 as a target in the construction of drug carriers for Parkinson's disease and in the preparation of targeted delivery systems for anti-Parkinson's disease drugs. Compared to other target receptors that cross the blood-brain barrier for targeted brain delivery, targeting GRP94 more specifically targets dopaminergic neurons in the substantia nigra, avoiding drug accumulation and neurotoxicity in normal intracranial regions.

The present invention discloses compounds of Formula (I) and their complexes with radionuclides that can recognize both Somatostatin type 2 receptor (SSTR2) and cholecystokinin 2 receptor (CCK2R) and can be used in the diagnosis and treatment of diseases where either or both receptors are overexpressed.

Disclosed are compositions, methods, and systems for imaging disease states using near-infrared fluorescent dyes conjugated to receptor-targeted molecules. In some aspects, a method for preparing an imaging agent includes covalently attaching a zwitterionic near-infrared fluorophore to a molecule containing a primary amino group, wherein the fluorophore comprises a sulfo-phenoxy substituent at the central methine carbon and sulfonic acid substituents at the 5-position of the indole nucleus. In some embodiments, the sulfo-phenoxy substituent imparts enhanced chemical stability to the dye, while the sulfonic acid substituents enable precise tuning of absorbance and emission maxima to desired near-infrared wavelengths. These features collectively facilitate the development of imaging agents with improved photostability, spectral properties, and conjugation efficiency for use in biomedical research and clinical diagnostics.

Genetically modified cells (e.g., recombinant mammalian cells) and methods for improving the expression / functional response of olfactory receptors are described herein. Genetically modified cells and methods can generally modulate the levels of chaperone proteins that help target receptors to the cell membrane. Genetically modified cells and methods can also provide a platform for use in studying the function of a broader group of chemosensory receptors, including taste receptors and TRP channels.

The application relates to an integrin receptor targeting polypeptide derivative and molecular probe and application. The integrin receptor targeting polypeptide derivative has a structure shown in formula I. The novel polypeptide derivative constructed by the application has the function of simultaneously coupling multiple imaging molecules, and can be simultaneously used for preoperative diagnosis and intraoperative guidance of multiple imaging methods. The research result can provide a new idea for further development of molecular imaging, and increase the range of clinical application of molecular imaging.

The application belongs to the technical field of genetic engineering, and provides Hsp60 receptor targeted recombinant plant lactobacillus, a construction method and application. The plant lactobacillus is used as a host, pPG612 is used as an expression vector, and CsgB genes or CsgF genes are expressed. Two strains of engineering probiotics can express target proteins and can stably express on the surface of the bacterial body, effectively adhere to AB.9 intestinal epithelial cells, and can inhibit the adhesion and invasion of AB.9 cells. A. veronii Secondly, the engineering probiotics LP-pPG-CsgB and LP-pPG-CsgF can promote the proliferation of dendritic cells, T lymphocytes and B lymphocytes, and improve the secretion of intestinal mucus IgT. The engineering bacteria can also competitively bind to the Hsp60 receptor of intestinal epithelial cells, down-regulate the expression of p65 through the TLR4 / TLR5 dependent NF-κB signal pathway, inhibit the activation of the NF-κB signal pathway, regulate the redistribution of intestinal tight junction proteins, and down-regulate the expression of pro-inflammatory factors. Furthermore, the engineering bacteria can increase the abundance of intestinal beneficial flora of the snakehead, and the flora can mediate and activate the immune response through the feeding environment.

The invention relates to the technical field of tumor treatment, and discloses a polymeric drug-loaded particle servo type controlled release system and method based on high-frequency oscillation excitation. The system comprises polymeric drug-loaded particles; the Doppler echo repositioning module is used for acquiring imaging information of the tumor tissue in real time and generating a servo-adjusted sound signal according to the imaging information; the array type ultrasonic unit is in communication connection with the Doppler echo re-positioning module and is used for receiving the sound signal subjected to servo adjustment and transmitting high-frequency ultrasound according to the sound signal; wherein when the high-frequency ultrasound acts on the polymeric drug-loaded particles, the polymeric drug-loaded particles are positioned on target tissues under the dual effects of tumor cell surface receptor targeting and subcellular structure targeting, and the sound-sensitive agent generates active oxygen under the excitation of the high-frequency ultrasound, so that the drug-loaded particles can be used for treating tumor cells. And the array type ultrasonic unit can adjust the ultrasonic excitation intensity in real time according to the imaging of the tumor tissue so as to realize the instantaneous active oxygen filling of the target tissue and reconstruct the tumor microenvironment.

The present invention provides a chimeric antigen-receptor targeting LRRC15, which exhibits drug efficacy against tumors associated with LRRC15 positive cells, and cells comprising the same.SOLUTION: To provide a chimeric antigen-binding receptor containing an anti- LRRC15 antigen-binding site containing a specific CDR, and to provide chimeric antigen-binding receptor-expressing cells containing the receptor.SELECTED DRAWING: None

This invention relates to the field of biomedicine, and in particular to a T-cell receptor targeting MAGE-A3 and its applications. The T-cell receptor provided by this invention comprises six CDR regions: CDR1α, CDR2α, and CDR3α in the TCRα chain, and CDR1β, CDR2β, and CDR3β in the TCRβ chain, with amino acid sequences shown in SEQ ID Nos. 1-6, respectively. This invention utilizes reverse-locking engineering to modify wild-type MAGE-A3 TCR molecules, obtaining a highly efficient and non-toxic TCR targeting MAGE-A3, avoiding the toxic side effects caused by affinity maturation. This engineered TCR is then applied to the preparation of TCR-T cells for the treatment of solid tumors.

This application provides umbilical cord blood-derived natural killer (CB-NK) cells engineered to express a chimeric receptor targeting ADGRE2. Pharmaceutical compositions, kits, and methods for treating cancer are also provided.

The present application relates to the technical field of biological medicine and gene therapy, and particularly relates to a nucleic acid delivery system targeting pancreatic beta cells and application thereof. The nucleic acid delivery system comprises a nanocomplex formed by a cationic polymer modified with a targeting ligand and siRNA; the targeting ligand is a GLP-1 receptor targeting peptide; the cationic polymer is a PEI-PFA polymer; and the siRNA is siRNA targeting DYRK1A. The present application provides a novel pancreatic beta cell targeting delivery platform for gene therapy of type 2 diabetes. The platform realizes beta cell function regeneration by precisely regulating DYRK1A gene expression, and has targeting, safety and high efficiency, thereby providing a new strategy with broad clinical application prospect for diabetes treatment.

The invention relates to the technical field of biological medicine and gene therapy, in particular to a nucleic acid delivery system for targeting pancreatic beta cells and application of the nucleic acid delivery system. The composition comprises a nano-composite formed by a cationic polymer modified by a targeting ligand and siRNA (small interfering Ribonucleic Acid), the targeting ligand is a GLP-1 receptor targeting peptide; the cationic polymer is a PEI-PFA polymer; and the siRNA is the siRNA of the target DYRK1A (DYRK1A). The invention provides a brand-new pancreatic beta cell targeted delivery platform for gene therapy of type 2 diabetes mellitus. The platform realizes beta cell function regeneration by accurately regulating and controlling DYRK1A gene expression, has targeting property, safety and high efficiency, and provides a new strategy with wide clinical application prospect for diabetes treatment.

Described herein are somatostatin subtype-2 receptor (SST2R)-targeted therapeutics that target tumor cells that express SST2R and their use in the treatment of cancer.

The present disclosure provides, inter alia, novel compounds targeting cholecystokinin-2 receptor (CCK2R) expressed on the surface of cancer cells. Also provided are methods for imaging, diagnosing, and / or treating cancers using the same.

The invention belongs to the field of organic matter preparation, and particularly relates to a rhodamine-labeled isoquinoline derivative as well as a preparation method and application thereof. According to the preparation method, Sigma-2 receptor targeting ligand 6, 7-dimethoxy tetrahydroisoquinoline is covalently linked with rhodamine fluorophore through a specific connecting bridge, so that a derivative containing rhodamine and a compound containing the 6, 7-dimethoxy tetrahydroisoquinoline are prepared. The rhodamine-labeled isoquinoline derivative disclosed by the invention can achieve the diagnosis and treatment effects through one-time administration, and has good biological activity, higher selectivity and lower toxicity.

Some embodiments of the methods and compositions provided herein include cells having membrane-tethered. IL13 mutein-directed zetakine receptors, such as those which specifically bind to the IL-13 receptor alpha 2 (IL13Ra2) at a 50-fold higher affinity than wild-type IL-13, and methods of cell-based immunotherapy targeting cancer cells, such as cells of solid tumors, using these compositions. In some embodiments, the receptors include spacer regions, such as particular spacer regions designed to provide certain advantages.

The invention is directed to T cells and other cells that express chimeric NK-p30 receptors (“chimeric NKp30 T cells”), methods of making and using chimeric NKp30 T cells, and methods of using these chimeric NKp30 T cells to address diseases and disorders. In one aspect, the disclosure broadly relates to chimeric NKp30 T cells, isolated populations thereof, and compositions comprising the same. In another aspect, said chimeric NKp30 T cells are further designed to express a functional non-TCR receptor. The disclosure also pertains to methods of making said chimeric NKp30 T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said chimeric NKp30 T cells, populations thereof, or compositions comprising the same.

This invention relates to the field of biomedical technology, and in particular to a T-cell receptor targeting the AFP peptide, its preparation method, and a companion diagnostic kit. A T-cell receptor targeting the AFP peptide, wherein the sequence of the AFP peptide is FMNKFIYEI, and the T-cell receptor contains a TCRα chain variable domain and a TCRβ chain variable domain, is provided. The corresponding nucleic acid molecule, vector, and host cell are provided, as well as a method for preparing the T-cell receptor. A companion diagnostic kit containing the cell receptor is further provided. This invention provides a better option for companion diagnostic and therapeutic products for alpha-fetoprotein (AFP) cells.